

## 23 May 2024

# **Argent BioPharma Ltd.**

# **Change of OTCQB Company Code**

Argent BioPharma Ltd. (**Argent BioPharma** or the **Company**) advises that as of 20 May 2024, the Company's new trading code on the OTCQB changed to **RGTLF**.

This adjustment aligns with the Company's recent change in registered name with the Australian Securities and Investments Commission (ASIC) and trading code on the ASX and LSE.

—Ends—

## Authorised for release by the board of directors, for further information please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@argentbiopharma.com

UK IR/PR Advisers
IFC Advisory
Graham Herring / Tim Metcalfe / Zach Cohen
+44 203 934 6630
argentbiopharma@investor-focus.co.uk

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6382 3390

info@argentbiopharma.com

UK Brokers
Oberon Capital
Aimee McCusker / Adam Pollock
+44 203 179 5300
aimeemccusker@oberoninvestments.com

adampollock@oberoninvestments.com

## **About Argent BioPharma**

Argent BioPharma purpose is to address unmet medical needs through the pioneering integration of Nanotechnology and Multidisciplinary research methods. Our approach heralds a transformative shift in healthcare, combining the power of multi-targeted drug therapies with precision nanoscale delivery to enhance treatment efficacy while reducing side effects. Central to our ethos is making these innovative treatments accessible, ensuring they reach those underserved by current medical solutions. As we endeavour to become globally recognized in the life science industry, we are committed to bridging healthcare gaps, redefining industry standards, and providing impactful solutions and hope to communities worldwide.

Follow us through our social media channels:

LinkedIn: Argent BioPharma Twitter: @ArgentBioPharma Facebook: Argent BioPharma